(insert text here)

Table of contents

  • Detailed, Expanded Analysis: Patient Profiler (US)
    • Patient Profiler - Psoriasis PPT [August 2018]

Author(s): Hailing Yang, PhD

Hailing Yang, is an analyst on the Immune and Inflammatory research team at Decision Resources Group, focusing primarily on psoriasis and psoriatic arthritis. In this role, he conducts primary research via interviews/surveys with medical experts and write market analysis deliverables designed for key decision-makers within the biopharmaceutical industry. Prior to joining DRG, Dr. Yang worked at Selecta Biosciences and Bioss USA Antibodies as a consultant. He studied brain cancer and received a from Tufts University, where he held an executive role for Tufts New England Case Competition. Dr. Yang earned a from Wuhan University in China.

Related Reports

Psoriasis | Emerging Therapies | Skyrizi Launch Tracking Wave 2 (US)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details